1 study found for:    22915637 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase of Disease
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years